Merck axes two of nine ADCs in pact with Kelun-Biotech
Merck has chosen not to pick up two preclinical antibody-drug conjugates from its partner Sichuan Kelun-Biotech, the Chinese drugmaker disclosed Monday.
The termination does not affect three clinical-stage ADCs that the companies are developing, including the Phase III breast and lung cancer asset SKB-264/MK-2870, Kelun said. Four other preclinical programs also remain in the deal.
Merck has made multiple pacts with Kelun since May 2022, promising as much as $12 billion across three deals for up to nine ADCs. With the small pullback announced Monday, Kelun saw its shares dip about 7%.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.